Ticker

ORLANDO, FL / ACCESS Newswire / August 6, 2026 / NexTel Medical Corp. (f/k/a Exousia Pro, Inc.) (OTCID:MAJI) ("NexTel" or the "Company") is issuing a clarification regarding statements made during an audio stream hosted yesterday afternoon with @SuperRobotGX. Baylor University Research Agreement Update During the presentation, Dr. Hausman referenced a study evaluating the anti-aging properties of Maxasome Plus in…

Strategic Acquisition Positions NexTel at the Forefront of Precision Neuro-Restoration with Xycota's Breakthrough Exosome-Delivered Brain Circuitry Repair Platform and Pending FDA Orphan Drug Designation ORLANDO, FL / ACCESS Newswire / August 5, 2026 / NexTel Medical Corp. (f/k/a Exousia Pro, Inc.) (OTCID:MAJI), today announced that it has executed a definitive Letter of Intent (LOI) to acquire 100% of Xycota…

Company targets a growing $1.2B+ North American pet oncology market leveraging proprietary exosome-based diagnostic technologies. ORLANDO, FL / ACCESS Newswire / July 28, 2026 / NexTel Medical Corp. (f/k/a Exousia Pro, Inc.) (OTC PINK:MAJI), a clinical-stage biotechnology company pioneering proprietary exosome-based delivery and diagnostic systems, today announced a major commercial expansion into veterinary…

Revised transaction expands NexTel's acquisition from JumpstartRx and NuevistraMed to Island 40 Group's broader growth platform, adding health services, pharmaceutical access, lab testing, institutional partnerships, and diversified revenue channels ORLANDO, Fla. , July 22, 2026 (GLOBE NEWSWIRE) -- NexTel Medical Corp. (f/k/a Exousia Pro, Inc. ) (OTCID: MAJI), a clinical-stage biotechnology company focused on…

Revised transaction expands NexTel's acquisition from JumpstartRx and NuevistraMed to Island 40 Group's broader growth platform, adding health services.